期刊
NANO TODAY
卷 29, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.nantod.2019.100801
关键词
Nanosized drug delivery systems; Nanoparticles; Biomimetic vehicles; PD-1/PD-L1 blockade; Cancer immunotherapy
资金
- National Natural Science Foundation of China [81690265, 81803444, 81521005]
- Strategic Priority Research Program of CAS [XDA12050307]
- Youth Innovation Promotion Association of CAS [2019283]
- Shanghai Sailing Program [19YF1457300]
Checkpoint blockade immunotherapy revolutionizes the field of cancer therapy, among which anti-programmed cell death (anti-PD) therapy is the most successful one in clinic. Despite the tremendous advancement, anti-PD therapy is still limited by barriers such as low response rate and immune related adverse effects (AEs), which are mainly resulted from poor intratumoral infiltration of cytotoxic T lymphocytes and off-tumor distribution of the anti-PD drugs. To address these issues, nanosized drug delivery systems (NDDS) have been fabricated to realize synergistic application with anti-PD drugs for anti-tumor immunity priming or enable targeting delivery of anti-PD drugs with versatile chemical properties. In this review, we summarize the major barriers for successful anti-PD therapy, highlight current advances in NDDS with improved anti-PD therapeutic benefits, and discussed the possible directions of the field. (C) 2019 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据